STINGing the Tumor's immune evasion mechanism

STINGing the Tumor's immune evasion mechanism

In order to enhance the STING dependent type I interferon (IFN) response, we formulated cyclic dinucleotides (CDN) with cancer vaccines to develop STINGVAX. Interestingly, tumors from STINGVAX treated mice demonstrated dramatic PD-L1 upregulation. When combined with PD-1 blockade, STINGVAX induced r...

Full description

Bibliographic Details
Main Author: Young J. Kim
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
adjuvants
cyclic dinucleotides
cancer vaccines
cancer vaccine
sting
tumor microenvironment
t-cells
Online Access:http://dx.doi.org/10.1080/2162402X.2015.1083673

Internet

http://dx.doi.org/10.1080/2162402X.2015.1083673

Similar Items